In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Buy rating on Dynavax (DVAX), with a price target of $30. The company’s shares closed yesterday at $11.12, close to its 52-week low of $9.63.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.5% and a 50.3% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Alexion Pharmaceuticals.
Currently, the analyst consensus on Dynavax is a Strong Buy with an average price target of $28.75, which is a 158.5% upside from current levels. In a report issued on October 22, RBC Capital also maintained a Buy rating on the stock with a $26 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $23.30 and a one-year low of $9.63. Currently, Dynavax has an average volume of 1.11M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body’s innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases.
